MARKET

DCTH

DCTH

Delcath Systems Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

17.91
+0.64
+3.71%
Closed 16:00 03/05 EST
OPEN
17.69
PREV CLOSE
17.27
HIGH
17.91
LOW
16.01
VOLUME
122.86K
TURNOVER
--
52 WEEK HIGH
25.18
52 WEEK LOW
3.770
MARKET CAP
111.93M
P/E (TTM)
0.0708
1D
5D
1M
3M
1Y
5Y
8-K: DELCATH SYSTEMS, INC.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT (EDGAR Online via COMTEX) -- Pursuant to Section 13 or 15(d) of...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 6d ago
Delcath Systems to Participate at Upcoming Virtual Investor Conferences
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today that management will participate at these upcoming virtual investor conferences:
GlobeNewswire · 02/11 14:00
Aquestive Therapeutics Strengthens Board of Directors with Appointments of Julie Krop, M.D., and Marco Taglietti, M.D., and Announces Resignation of Douglas K. Bratton from Board of Directors
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients' unmet needs and solve therapeutic problems, today announced the appointment of Julie Krop, M.D., ...
GlobeNewswire · 02/09 12:30
Neuroendocrine Carcinoma Treatment Market Global Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast 2020 to 2027
Feb 09, 2021 (Market Insight Reports) -- The Neuroendocrine Carcinoma Treatment research is an astute report with intricate details for studying appropriate...
Market Insight Reports · 02/09 12:03
Green Energy Market [Trending PDF] Excessive Growth Opportunities Estimated to Be Experienced 2021-2030 | GE Energy Services Inc, ABB Ltd
Jan 29, 2021 (MarketResearch.biz via Comtex) -- A consciously conceived and designed business intelligence report titled Global Green Energy market 2021 by...
marketresearch.biz · 01/29 11:00
Biliary Tract Cancers Report Insights
ABNewswire · 01/28 15:42
Prepared Dry-Foods Market Industry To Reach A New Threshold of Growth By 2030 | Oregon Freeze Dry Inc, ConAgra Foods Inc
Jan 28, 2021 (WiredRelease via Comtex) -- A consciously conceived and designed business intelligence report titled Global Prepared Dry-Foods market 2021 by...
marketresearch.biz · 01/28 07:04
Underground Cabling EPC Market Gross Margin, Revenue | 2021-2030, Production and Tremendous Growth | Arteche, ZTT
Jan 21, 2021 (WiredRelease via Comtex) -- A consciously conceived and designed business intelligence report titled Global Underground Cabling EPC market...
marketresearch.biz · 01/21 07:15
More
Forecast
Actual (B USD)
Estimate (B USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of DCTH. Analyze the recent business situations of Delcath Systems Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average DCTH stock price target is 20.67 with a high estimate of 23.00 and a low estimate of 19.00.
EPS
Institutional Holdings
Institutions: 38
Institutional Holdings: 2.02M
% Owned: 32.25%
Shares Outstanding: 6.25M
TypeInstitutionsShares
Increased
2
18.71K
New
18
1.84M
Decreased
5
15.88K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
+2.73%
Healthcare Equipment & Supplies
+2.13%
Key Executives
Non-Executive Chairman/Independent Director
Roger Stoll
Chief Executive Officer/Director
Gerard Michel
Chief Operating Officer/Executive Vice President
John Purpura
Chief Accounting Officer
Christine Padula
Independent Director
Gilad Aharon
Independent Director
Elizabeth Czerepak
Independent Director
Steven Salamon
Independent Director
John Sylvester
No Data
About DCTH
Delcath Systems, Inc. is a late-stage clinical development company with early commercial activity in Europe focused on cancers of the liver. The Company is a specialty pharmaceutical and medical device company developing its product, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS). The Company's system delivers and filters melphalan hydrochloride, which is marketed as a device under the trade name Delcath Hepatic CHEMOSAT Delivery System for Melphalan (CHEMOSAT). The Company's focus is on the execution of the clinical development program (CDP) in ocular melanoma liver metastases (mOM), intrahepatic cholangiocarncinoma (ICC), hepatocellular carcinoma (HCC or primary liver) and other cancers that are metastatic to the liver.

Webull offers kinds of Delcath Systems Inc stock information, including NASDAQ:DCTH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DCTH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading DCTH stock methods without spending real money on the virtual paper trading platform.